PD-L1 antibody

DRUG3 trials

Sponsors

West China Hospital, N.N. Alexandrov National Cancer Centre, Fudan University

Conditions

Hepato Cellular Carcinoma (HCC)Locally Advanced Colorectal CancerMetastatic Cervical CancerPersistent Cervical CancerRecurrent Cervical Cancer

Phase 2

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

RecruitingNCT06742424

West China HospitalHepato Cellular Carcinoma (HCC)

Start: 2024-10-01End: 2027-07-30Target: 36Updated: 2024-12-19

PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer

RecruitingNCT07472153

N.N. Alexandrov National Cancer CentreMetastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer

Start: 2025-07-01End: 2033-06-30Target: 120Updated: 2026-03-16

Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

Not yet recruitingNCT07503639

Fudan UniversityLocally Advanced Colorectal Cancer

Start: 2026-04-01End: 2030-04-01Target: 134Updated: 2026-03-31